These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 27254953

  • 1. [LAMA/LABA fixed dose combination for treatment of COPD].
    Kuwahira I.
    Nihon Rinsho; 2016 May; 74(5):820-6. PubMed ID: 27254953
    [Abstract] [Full Text] [Related]

  • 2. Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.
    Kalberg C, O'Dell D, Galkin D, Newlands A, Fahy WA.
    Drugs R D; 2016 Jun; 16(2):217-27. PubMed ID: 27028749
    [Abstract] [Full Text] [Related]

  • 3. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
    Ismaila AS, Haeussler K, Czira A, Tongbram V, Malmenäs M, Agarwal J, Nassim M, Živković-Gojović M, Shen Y, Dong X, Duarte M, Compton C, Vogelmeier CF, Halpin DMG.
    Adv Ther; 2022 Nov; 39(11):4961-5010. PubMed ID: 35857184
    [Abstract] [Full Text] [Related]

  • 4. Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study.
    Hsieh MJ, Chen NH, Cheng SL, Tao CW, Wei YF, Wu YK, Chan MC, Liu SF, Hsu WH, Yang TM, Lin MS, Liu CL, Kuo PH, Tsai YH.
    Int J Chron Obstruct Pulmon Dis; 2022 Nov; 17():967-976. PubMed ID: 35510163
    [Abstract] [Full Text] [Related]

  • 5. Recent advances in COPD disease management with fixed-dose long-acting combination therapies.
    Bateman ED, Mahler DA, Vogelmeier CF, Wedzicha JA, Patalano F, Banerji D.
    Expert Rev Respir Med; 2014 Jun; 8(3):357-79. PubMed ID: 24802656
    [Abstract] [Full Text] [Related]

  • 6. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.
    Kerwin EM, Kalberg CJ, Galkin DV, Zhu CQ, Church A, Riley JH, Fahy WA.
    Int J Chron Obstruct Pulmon Dis; 2017 Jun; 12():745-755. PubMed ID: 28280319
    [Abstract] [Full Text] [Related]

  • 7. Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study.
    Kaplan A, Chapman KR, Anees SM, Mayers I, Rochdi D, Djandji M, Préfontaine D, McIvor A.
    Int J Chron Obstruct Pulmon Dis; 2019 Jun; 14():249-260. PubMed ID: 30718952
    [Abstract] [Full Text] [Related]

  • 8. Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis.
    Huisman EL, Cockle SM, Ismaila AS, Karabis A, Punekar YS.
    Int J Chron Obstruct Pulmon Dis; 2015 Jun; 10():1863-81. PubMed ID: 26392761
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial.
    Rhee CK, Park HY, Park JW, Lee JH, Kim TH, Lee SW, Jung JY, Kim S, Hwang YI, Jung KS.
    Trials; 2017 Feb 22; 18(1):80. PubMed ID: 28228162
    [Abstract] [Full Text] [Related]

  • 10. Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives.
    Rhee CK, Yoshisue H, Lad R.
    Adv Ther; 2019 Mar 22; 36(3):495-519. PubMed ID: 30742242
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
    Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR.
    Int J Chron Obstruct Pulmon Dis; 2017 Mar 22; 12():997-1008. PubMed ID: 28392684
    [Abstract] [Full Text] [Related]

  • 12. Dual bronchodilator therapy for chronic obstructive pulmonary disease: evidence for the efficacy and Safety of fixed dose combination treatments in the setting of recent guideline updates.
    Deas SD, Huprikar N.
    Curr Opin Pulm Med; 2018 Mar 22; 24(2):130-137. PubMed ID: 29206657
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis.
    Miravitlles M, Urrutia G, Mathioudakis AG, Ancochea J.
    Respir Res; 2017 Nov 25; 18(1):196. PubMed ID: 29178871
    [Abstract] [Full Text] [Related]

  • 14. The impact of indacaterol/glycopyrronium fixed-dose combination versus tiotropium monotherapy on lung function and treatment preference: a randomized crossover study - the FAVOR study.
    Kardos P, Hagedorn-Peinz I.
    Int J Chron Obstruct Pulmon Dis; 2018 Nov 25; 13():69-77. PubMed ID: 29317812
    [Abstract] [Full Text] [Related]

  • 15. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies.
    Palli SR, Xie B, Chastek B, Elliott CA, Bengtson LGS.
    J Manag Care Spec Pharm; 2021 Jul 25; 27(7):810-824. PubMed ID: 33764161
    [Abstract] [Full Text] [Related]

  • 16. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.
    Feldman GJ, Sousa AR, Lipson DA, Tombs L, Barnes N, Riley JH, Patel S, Naya I, Compton C, Alcázar Navarrete B.
    Adv Ther; 2017 Nov 25; 34(11):2518-2533. PubMed ID: 29094315
    [Abstract] [Full Text] [Related]

  • 17. A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease.
    Muraki M, Kunita Y, Shirahase K, Yamazaki R, Hanada S, Sawaguchi H, Tohda Y.
    BMC Pulm Med; 2021 Jan 13; 21(1):26. PubMed ID: 33441146
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol.
    Moretz C, Bengtson LG, Sharpsten L, Koep E, Le L, Tong J, Stanford RH, Hahn B, Ray R.
    Int J Chron Obstruct Pulmon Dis; 2019 Jan 13; 14():2047-2060. PubMed ID: 31564852
    [Abstract] [Full Text] [Related]

  • 19. Relationship between lung function and inhalation devices for LAMA/LABA therapy for chronic obstructive pulmonary disease.
    Yamada H, Hida N, Satoh H, Nakaizumi T, Terashima H, Hizawa N.
    Chron Respir Dis; 2018 Nov 13; 15(4):419-420. PubMed ID: 29152998
    [No Abstract] [Full Text] [Related]

  • 20. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.
    Feldman GJ, Edin A.
    Ther Adv Respir Dis; 2013 Dec 13; 7(6):311-9. PubMed ID: 24004659
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.